Radiopharm receives $8M to fund clinical trials

The facility is due by October 26, 2027, with repayment timed to follow the anticipated FY26 RDTI receipt.

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd (RADX) received $8,000,000 from Rockford Capital under a funding facility secured against the company’s anticipated FY26 Research and Development Tax Incentive (RDTI). The company said it will use the funds to support its clinical trial pipeline and general working capital.

The facility carries interest at a commercial rate, with repayment timed to follow receipt of the anticipated FY26 RDTI and due by October 26, 2027. Radiopharm may repay it earlier without penalty. The Australian Government program provides eligible companies a refundable tax offset of up to 43.5%.

Filing Explained

This Form 6-K attaches Radiopharm’s October 26 Australian-market announcement and incorporates it into the company’s Form F-3 registration statement, making the announcement part of that registration statement.

Key Figures

Advance received: $8,000,000 Facility repayment due: October 26, 2027 RDTI refundable tax offset: Up to 43.5% +2 more

5 metrics

Advance received $8,000,000 From Rockford Capital under a funding facility

Facility repayment due October 26, 2027 Repayment is timed to follow anticipated receipt of FY26 RDTI

RDTI refundable tax offset Up to 43.5% Australian Government program for companies engaging in eligible activities

Phase 2 trials 1 trial Clinical program

Phase 1 trials 5 trials Clinical program

Key Terms

Research and Development Tax Incentive (RDTI), refundable tax offset, funding facility, clinical stage

4 terms

Research and Development Tax Incentive (RDTI) regulatory

"anticipated FY26 Research and Development Tax Incentive (RDTI)"

refundable tax offset regulatory

"with a refundable tax offset of up to 43.5%"

funding facility financial

"under a funding facility secured against"

clinical stage medical

"a clinical stage radiotherapeutics company"

The clinical stage describes where a drug or medical treatment is in testing on human volunteers or patients, usually categorized by early safety testing through larger effectiveness trials. For investors it signals how much human evidence exists and how close the product may be to approval or market entry—a bit like a prototype moving from lab bench trials to real-world beta tests, with each step reducing uncertainty and creating potential value catalysts.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did RADX receive from Rockford Capital?

Radiopharm received $8,000,000 from Rockford Capital under a facility secured against its anticipated FY26 RDTI. The company said the funds will support its clinical trial pipeline and general working capital.

When is RADX’s Rockford Capital facility due?

Repayment is due by October 26, 2027, timed to follow the anticipated receipt of FY26 RDTI. Radiopharm may repay the facility at any time before that date without penalty; interest is charged at a commercial rate.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 08:00 AM EDT Accepted by SEC EDGAR 10/26/2026 - 08:00 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2026

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on October 26, 2026 titled:

“Radiopharm receives $8M advance on FY26 R&D tax incentive”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This Form 6-K, including the exhibits hereto, is incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-292178) and forms part thereof to the extent not superseded by documents or reports subsequently filed by the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934.

1

EXHIBITS

Exhibit Number		Description
99.1		Radiopharm receives $8M advance on FY26 R&D tax incentive

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: October 26, 2026	By:	/s/ Amritha Sushil
		Amritha Sushil
		Company Secretary

3

Exhibit 99.1

ASX ANNOUNCEMENT
26 October 2026  

Radiopharm receives $8M advance on FY26 R&D tax incentive

Sydney, Australia – 26 October 2026 – Radiopharm Theranostics Limited (ASX: RAD; Nasdaq:RADX), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has received $8,000,000 from Rockford Capital under a funding facility secured against Radiopharm’s anticipated FY26 Research and Development Tax Incentive (RDTI).

The funds will support the clinical trial pipeline and otherwise for general working capital of the Company. The funding agreement with Rockford Capital provides Radiopharm with early access to a portion of the Company’s anticipated FY26 RDTI. The facility is secured against the anticipated FY26 RDTI to be received from the Australian Taxation Office, with interest charged at a commercial rate. Repayment is timed to follow the anticipated receipt of the Company’s FY26 RDTI, and is due by 26 October 2027. The facility can be repaid at any time without penalty prior to this date.

The Australian Government RDTI program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, prostate and brain. Learn more at radiopharmtheranostics.com.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
E: paulhopper@lifescienceportfolio.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/

Radiopharm Theranostics Limited

Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia

ABN: 57 647 877 889

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 RADIOPHARM RECEIVES $8M ADVANCE ON FY26 R&D TAX INCENTIVE 9.4 KB